Positron emission tomography in non-small-cell lung cancer: Prediction of response to chemotherapy by quantitative assessment of glucose use

Journal of Clinical Oncology

Volumn 21, Issue 14, 2003, Pages 2651-2657

  Weber, Wolfgang A ^a   Petersen, Volker ^a   Schmidt, Burkhard ^a   Tyndale Hines, Leishia ^a   Link, Thomas ^a   Peschel, Christian ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; FLUORODEOXYGLUCOSE; PLATINUM; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CONTROLLED STUDY; DRUG RESEARCH; HUMAN; IMAGING; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; TUMOR VOLUME; AGED; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; LUNG TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; SCINTISCANNING; SURVIVAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CONFIDENCE INTERVALS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0042631398     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.12.004     Document Type: Article

References (34)

1. Pieterman RM, van Putten JW, Meuzelaar JJ, et al: Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343:254-261, 2000
2. van Tinteren H, Hoekstra OS, Smit EF, et al: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomised trial. Lancet 359:1388-1393, 2002
3. Minn H, Zasadny KR, Quint LE, et al: Lung cancer: Reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 196:167-173, 1995
4. Weber WA, Ziegler SI, Thodtmann R, et al: Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40:1771-1777, 1999
5. Spaepen K, Stroobants S, Dupont P, et al: Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: Is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414-419, 2001
6. Schulte M, Brecht-Krauss D, Werner M, et al: Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 40:1637-1643, 1999
7. Wahl RL, Zasadny K, Helvie M, et al: Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation. J Clin Oncol 11:2101-2111, 1993
8. Jansson T, Westlin JE, Ahlstrom H, et al: Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation? J Clin Oncol 13:1470-1477, 1995
9. Bassa P, Kim EE, Inoue T, et al: Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 37:931-938, 1996
10. Schelling M, Avril N, Nahrig J, et al: Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695, 2000
11. Smith IC, Welch AE, Hutcheon AW, et al: Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18:1676-1688, 2000
12. Brucher BL, Weber W, Bauer M, et al: Neoadjuvant therapy of esophageal squamous cell carcinoma: Response evaluation by positron emission tomography. Ann Surg 233:300-309, 2001
13. Flamen P, Van Cutsem E, Lerut A, et al: Positron emission tomography for assessment of the response to induction chemotherapy in locally advanced esophageal cancer. Ann Oncol 13:361-368, 2002
14. Weber WA, Ott K, Becker K, et al: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058-3065, 2001
15. Breathnach OS, Freidlin B, Conley B, et al: Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results. J Clin Oncol 19:1734-1742, 2001
16. Sekine I, Tamura T, Kunitoh H, et al: Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer. Ann Oncol 10:731-733, 1999
17. Shepherd FA: Chemotherapy for advanced non-small-cell lung cancer: Modest progress, many choices. J Clin Oncol I8:35S-8S, 2000 (suppl)
18. Shepherd FA, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
19. Fossella FV, DeVore R, Kerr RN, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18:2354-2362, 2000
20. Dy GK, Adjei AA: Novel targets for lung cancer therapy: Part I. J Clin Oncol 20:2881-2894, 2002
21. Herbst RS, Maddox AM, Rothenberg ML, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20:3815-3825, 2002
22. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
23. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
24. Wienhard K, Dahlbom M, Eriksson L, et al: The ECAT EXACT HR: Performance of a new high resolution positron scanner. J Comput Assist Tomogr 18:110-118, 1994
25. Metz CE: Some practical issues of experimental design and data analysis in radiological ROC studies. Invest Radiol 24:234-245, 1989
26. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al: Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: A prospective pilot study-The Leuven Lung Cancer Group [in process citation]. Ann Oncol 9:1193-1198, 1998
27. Akhurst T, Downey RJ, Ginsberg MS, et al: An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg 73:259-264, 2002
28. Ryu JS, Choi NC, Fischman AJ, et al: FDG-PET in staging and restaging non-small cell lung cancer after nepadjuvant chemoradiotherapy: Correlation with histopathology. Lung Cancer 35:179-187, 2002
29. Shields AF, Mankoff DA, Link JM, et al: Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 39:1757-1762, 1998
30. Hoekstra CJ, Hoekstra OS, Stroobants SG, et al: Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 43:1304-1309, 2002
31. Borges M, Sculier JP, Paesmans M, et al: Prognostic factors for response to chemotherapy containing platinum derivatives in patients with unresectable non-small cell lung cancer. (NSCLC). Lung Cancer 16:21-33, 1996
32. Kawasaki M, Nakanishi Y, Kuwano K, et al: Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 34:1352-1357, 1998
33. Monzo M, Rosell R, Sanchez JJ, et al: Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17:1786-1793, 1999
34. Beer DG, Kardia SL, Huang CC, et al: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8:816-824, 2002